Bionano Genomics (BNGO) Revenue (2017 - 2026)

Bionano Genomics (BNGO) has 10 years of Revenue data on file, last reported at $6.7 million in Q1 2026.

• For the quarter ending Q1 2026, Revenue rose 3.56% year-over-year to $6.7 million; the trailing twelve-month figure through Mar 2026 stood at $28.7 million (up 0.96% YoY), and the FY2025 full-year result was $28.5 million, down 7.37% from the prior year.
• Revenue fell to $6.7 million in Q1 2026, from $8.0 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $10.7 million in Q4 2023 to a low of $5.7 million in Q1 2022.
• A 5-year average of $7.6 million and a median of $7.4 million in 2023 frame the typical range for Revenue.
• Across the five-year window, Revenue surged 79.8% in 2022 and sank 34.83% in 2024, its largest moves.
• Tracing BNGO's Revenue over 5 years: stood at $8.2 million in 2022, then soared by 30.51% to $10.7 million in 2023, then retreated by 23.86% to $8.2 million in 2024, then fell by 2.6% to $8.0 million in 2025, then declined by 15.9% to $6.7 million in 2026.
• Business Quant data shows BNGO's Revenue at $6.7 million in Q1 2026, $8.0 million in Q4 2025, and $7.4 million in Q3 2025.